Quibim was founded in 2015 by Luis Marti Bonmati and Angel Alberich Bayarri. The company specializes in quantitative imaging of biomarkers and medical applications in precision medicine. Quibim develops foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans. The company has offices in Madrid, Barcelona, New York (USA), and Cambridge (UK), and maintains wholly owned subsidiaries in the USA and the UK.
As of March 2026, Quibim has approximately 113 employees across 3 continents. On January 28, 2025, Quibim raised $50 million in a Series A funding round. Quibim has secured a global partnership with Philips to integrate its AI models into Philips' MR scanners and partnerships with pharmaceutical companies such as Merck KGaA to enhance clinical trials and accelerate drug development. The company has obtained regulatory clearances such as CE, UKCA, and FDA 510(k) for products like QP-Prostate and QP-Brain, as well as CE and UKCA for QP-Liver.
In 2024, the company was identified by Tech Tour Growth50 as a potential future European unicorn and Great Place to Work Spain named it one of the Best Workplaces in Technology. In April 2026, Quibim partnered with Germany's Vara to bring Europe's leading breast-cancer screening AI to Spain.
Facts compiled by Executive Moves from publicly available news and press releases on 4 June 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Quibim team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
